Synergistic effect of triptolide and tacrolimus on rat cardiac allotransplantation

Japanese Heart Journal

Volumn 45, Issue 4, 2004, Pages 657-665

  Li, Ruzheng ^a,b   Takazawa, Kenji ^a   Suzuki, Hiromasa ^a   Hariya, Akifusa ^a   Yamamoto, Taira ^a   Matsushita, Satoshi ^a   Hirose, Hitoshi ^a   Amano, Atsushi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Cardiac allografts; Combination therapy; Immunosuppression; Tacrolimus; Triptolide

Indexed keywords

PLACEBO; TACROLIMUS; TRIPTOLIDE; DITERPENE; IMMUNOSUPPRESSIVE AGENT; PHENANTHRENE DERIVATIVE;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG EFFECT; EVALUATION; IMMUNOLOGY; LEWIS RAT;

ANIMALS; DITERPENES; DRUG SYNERGISM; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; MALE; PHENANTHRENES; RATS; RATS, INBRED LEW; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 6344240731     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.45.657     Document Type: Article

References (24)

1. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083-91.
2. Ochiai T, Nakajima K, Hashimoto M, et al. Effect of a new immunosuppressive agent, FK506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 1987; 19: 1284-6.
3. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK506. Immunol Today 1992; 13: 136-42.
4. Liu J, Farmer JJ, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporine A and FK506 complexes. Cell 1991; 66: 807-15.
5. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925-75.
6. Kino T, Inamura N, Sakai F, et al. Effect of FK506 on human mixed lymphocyte reaction in vitro. Transplant Proc 1987; 19: 36-9.
7. Jain A, Reyes J, Kashyap R, et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc 1998; 30: 1403-4.
8. Woodle ES, Thistlethwaite JR, Gordon JH. Tacrolimus therapy for refractory acute renal allograft rejection: A prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. Transplant Proc 1996; 28: 3163-4.
9. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: Intermediate-term results. J Thorac Cardiovasc Surg 1996; 111: 764-72.
10. Hebert MF, Ascher NL, Lake JR, Robert JP. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. Transplantation Proc 1991; 23: 3109-10.
11. Tao XL, Sun Y, Dong Y, et al. A prospective, controlled, double blind, cross-over study of tripterygium wilfordii hook F in treatment of rheumatoid arthritis. Chin Med J 1989; 102: 327-32.
12. Tao X, Davis LS, Lipsky PE. Effect of an extract of the Chinese herbal remedy Tripterygium Wilfordii Hook F on human immune responsiveness. Arthritis Rheum 1991; 34: 1274-81.
13. Gu WZ, Chen R, Brandwein S, McAlpine J, Burres N. Isolation, purification and characterization of immunosuppressive compounds from tripterygium: triptolide and tripdiolide. Int J Immunopharmacol 1995; 17: 351-6.
14. Yang SX, Xie SS, Gao HL, Ma DL, Long ZZ. Triptolide suppresses T-lymphocyte proliferation by inhibiting interleukin-2 receptor expression, but spares interleukin-2 production and mRNA expression. Int J Immunopharmacol 1994; 16: 895-904.
15. Lu H, Hachida M, Enosawa S, Li XK, Suzuki S, Koyanagi H. Immunosuppressive effect of triptolide in vitro. Transplant Proc 1999; 31: 2056-7.
16. Yang SX, Gao HL, Xie SS, Zhang WR, Long ZZ. Immunosuppression of triptolide and its effect on skin allograft survival. Int J Immunopharmacol 1992; 14: 963-9.
17. Wang J, Xu R, Jin R, Chen Z, Fidler JM. Immunosuppressive activity of the Chinese medicinal plant Triptergium wilfordii. I. Prolongation of rat cardiac and renal allograft survival by the PG27 extract and immunosuppressive synergy in combination therapy with cyclosporine. Transplantation 2000; 70: 447-55.
18. Qiu D, Zhao G, Aoki Y, et al. Immunosuppressant PG490 (triptolide) inhitits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999; 274: 13443-50.
19. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1959; 57: 225.
20. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression: a critical review. Clin Exp Immunol 1977; 28: 1-18.
21. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantion. J Heart Transplant 1990; 9: 587-93.
22. McMaster P, Buist L. FK506 in transplantation. Transplant Proc 1993; 25: 2684-5.
23. Gudmundsdottir H, Turka LA. T cell costimulatory blockade: new therapies for transplant rejection. J Am Soc Nephrol 1999; 10: 1356-65.
24. Kay JE, Benzie CR. T lymphocyte activation through the CD28 pathway is insensitive to inhibition by the immunosuppressive drug FK506. Immunol lett 1989; 23: 155-60.